Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis (ECNM).

[1]  M. Triggiani,et al.  Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification , 2020, Allergy.

[2]  M. Triggiani,et al.  International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. , 2019, The Lancet. Haematology.

[3]  M. Triggiani,et al.  The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. , 2019, The journal of allergy and clinical immunology. In practice.

[4]  P. Valent,et al.  Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. , 2017, Blood.

[5]  C. Bindslev‐Jensen,et al.  Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population‐based study , 2016, American journal of hematology.

[6]  M. Triggiani,et al.  Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients , 2016, American journal of hematology.

[7]  K. Sotlar,et al.  Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. , 2015, The Journal of allergy and clinical immunology.

[8]  K. Brockow.  Epidemiology, prognosis, and risk factors in mastocytosis. , 2014, Immunology and allergy clinics of North America.

[9]  M. Triggiani,et al.  Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma , 2014, Leukemia.

[10]  C. Bindslev‐Jensen,et al.  KIT D816V Mutation-Positive Cell Fractions in Lesional Skin Biopsies from Adults with Systemic Mastocytosis , 2013, Dermatology.

[11]  H. Pehamberger,et al.  Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM). , 2013, American Journal of Blood Research.

[12]  B. Nedoszytko,et al.  Clinical aspects of paediatric mastocytosis: a review of 101 cases , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  I. Alvarez-Twose,et al.  Childhood mastocytosis , 2012, Current opinion in pediatrics.

[14]  A. Órfão,et al.  Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis , 2012, Allergy.

[15]  W. Biernat,et al.  Diffuse cutaneous mastocytosis: analysis of 10 cases and a brief review of the literature , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[16]  Kristen Gonter-Aubin,et al.  Systemic Mastocytosis , 2010, Handbook of Hematologic Malignancies.

[17]  W. Pickl,et al.  H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. , 2010, Experimental hematology.

[18]  L. Thomas,et al.  Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. , 2010, The Journal of investigative dermatology.

[19]  A. Órfão,et al.  Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. , 2009, The Journal of allergy and clinical immunology.

[20]  A. Tefferi,et al.  Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. , 2009, Blood.

[21]  Olivier Hermine,et al.  Phenotypic and Genotypic Characteristics of Mastocytosis According to the Age of Onset , 2008, PloS one.

[22]  A. Carrato,et al.  Mastocitosis sistémica: Revisión sistemática , 2008 .

[23]  M. Triggiani,et al.  Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria , 2007, European journal of clinical investigation.

[24]  P. Valent,et al.  FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis , 2007, European journal of clinical investigation.

[25]  Hua Xie,et al.  Inhibition of tryptase release from human colon mast cells by histamine receptor antagonists. , 2005, Asian Pacific journal of allergy and immunology.

[26]  J. Bennett,et al.  Diagnosis and treatment of systemic mastocytosis: state of the art , 2003, British journal of haematology.

[27]  L. Scott,et al.  Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease. , 2002, Archives of dermatology.

[28]  K. Lennert,et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.

[29]  J. Bernhard,et al.  Mastocytosis , 1997, The Lancet.

[30]  D. Metcalfe,et al.  Classification and diagnosis of mastocytosis: current status. , 1991, The Journal of investigative dermatology.

[31]  K. Lennert,et al.  Tissue mast cells in health and disease. , 1985, Pathology, research and practice.

[32]  K. Lennert,et al.  Mast cells and mast cell neoplasia: a review * , 1979, Histopathology.

[33]  R. Caplan.  The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases. , 1963, Archives of dermatology.

[34]  Massimo Triggiani,et al.  Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. , 2016, The Journal of allergy and clinical immunology.

[35]  F. Sim,et al.  Mastocytosis (Mast Cell Disease) , 2008 .

[36]  Karin Hartmann,et al.  Pediatric mastocytosis. , 2000, Hematology/oncology clinics of North America.